10月20日，查尔斯河盘中上涨5.06%，报314.95美元，成交额9480.4万美元。
此次异动的直接催化来自近期机构继续上调目标价。最新消息显示，摩根大通将公司目标价由310美元上调至345美元；更早前，摩根士丹利也将目标价由300美元上调至340美元，均维持偏积极看法。
与此同时，公司近期还宣布与Magellan Stem Cells合作，为其骨关节炎干细胞疗法提供基于下一代测序的病毒安全检测支持。叠加公司此前重申全年调整后每股收益指引处于11.15至11.45美元区间上沿，市场对其中长期增长预期有所强化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.